Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

EVAXBullishIndustry Newsnews

High materiality8/10

EVX-01 phase 2 melanoma data shows 75% ORR with durable responses

Oct 2, 2026, 9:25 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong early signals (ORR 75%, durable responses) paired with major conference catalysts (SITC, ESMO) can attract buyers ahead of presentations; historical biotech data read-through often drives volatility near data events, with upside if durability persists.

AI summary

What happened, with direct paths to the underlying reporting

Evaxion reports new EVX-01 immune data from a phase 2 melanoma trial with pembrolizumab, showing systemic immune modulation beyond vaccine responses. Two-year data show ORR 75% (12/16) with four complete responses; 92% remain in response and no relapses. SITC 2026 and ESMO 2026 presentations could drive upside if durability and standalone efficacy persist.

Phase 2 melanoma data: ORR 75% (12/16) with 4 CRs.
2-year durability: 92% still responding; no relapses observed.
86% of EVX-01 neoantigen targets triggered tumor-specific responses.
Three-year data to be presented at ESMO 2026 on Oct 24.
SITC 2026 will feature EVX-01 oral and poster data with pembrolizumab.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.